Menu
Localized theranostic solutions that revolutionize how bacterial infections are diagnosed and treated. Combine precision imaging with targeted interventions to improve patient outcomes.
Detect → Target → Treat
Experience the future of infection management with targeted imaging and treatment solutions that guide critical surgical decisions.
Currently in Phase 0 development, our 89Zirconium-labeled 1D9 antibody enables precise PET imaging of bacterial infections in vivo. This real-time imaging helps localize infections, allowing surgeons to make accurate decisions.
89Zirconium antibody improves real-time detection for surgical precision.
We are also exploring fluorescent labeling for use in near-infrared imaging during surgeries. This approach enhances the visibility of bacteria in real-time, improving the precision of infection detection.
Fluorescent labeling increases visibility for targeted intervention.
Zirconium-based near-infrared agents for precision diagnosis and image-guided surgery. Administered through a single bolus injection, our zirconium-based agents offer exceptional precision for bacterial detection and surgical guidance.
Our preclinical research demonstrates the effectiveness of 1D9 when conjugated with IRDye700DX and used with photodynamic therapy. This method can precisely eradicate MRSA without harming healthy tissue, offering a novel solution for difficult-to-treat infections.
aPDT is precise bacterial eradication without harming healthy cells.
Bringing precision and speed to diagnostics outside the body with the point of care applications.
We are developing point-of-care diagnostics using the 1D9 antibody combined with bioluminescence for rapid detection of S. aureus infections in synovial fluid (from joint samples). This innovation significantly reduces the time to diagnosis, from days to mere minutes.
We are also developing rapid nasal swab tests to identify Staphylococcus aureus carriers. Early detection in hospital settings will help prevent the spread of these infections.